4KB.F

Healthcare Biotechnology

Krystal Biotech, Inc.

€285.50

-6.10 -2.09% today

Price History

Not enough data

Key Stats

Market Cap

8.45B

Avg Volume

P/E (TTM)

41.74

EPS

€6.84

52W High

€330.30

52W Low

€153.25

Div. Yield

0.0%

Valuation

Forward P/E

-78.22

P/B Ratio

7.00

P/S Ratio

19.18

EV/EBITDA

38.20

EV/Revenue

17.29

Margins

Gross Margin 94.6%

Operating Margin 49.0%

Net Margin 54.8%

EBITDA Margin 45.2%

Growth & Returns

Revenue Growth (YoY)

24.1%

Earnings Growth (YoY)

38.8%

Earnings Growth (QoQ)

42.9%

Return on Equity

20.1%

Return on Assets

9.4%

Liquidity & Leverage

Current Ratio

8.32

Quick Ratio

7.73

Debt / Equity

0.01

Total Cash

845.63M

Total Debt

8.85M

About

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.